MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$50,529K
Net Income
-$62,513K
Net Profit Margin
-123.72%
EPS
-$1.04
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenues
50,529
51,718
57,216
56,258
Cost of goods sold excluding amortization
3,560
3,159
3,833
2,954
Research and development
36,953
28,435
29,006
22,563
Selling, general and administrative
71,838
68,361
62,978
60,273
Intangible asset amortization
1,987
1,987
1,752
1,752
Total operating expenses
114,338
101,942
97,569
87,542
Loss from operations
-63,809
-50,224
-40,353
-31,284
Other income, net
1,425
1,800
2,351
2,894
Loss before income taxes
-62,384
-48,424
-38,002
-28,390
Provision (benefit) for income taxes
129
143
103,185
-5,804
Net loss
-62,513
-48,567
-141,187
-22,586
Basic EPS
-1.04
-0.82
-2.389
-0.38
Diluted EPS
-1.04
-0.82
-2.389
-0.38
Basic Average Shares
60,226,570
59,459,982
59,107,385
59,091,478
Diluted Average Shares
60,226,570
59,459,982
59,107,385
59,091,478
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$62,513K
(-129.77%↓ Y/Y)
Loss before income
taxes
-$62,384K
(-78.82%↓ Y/Y)
Provision (benefit) for
income taxes
$129K
(101.68%↑ Y/Y)
Other income, net
$1,425K
(-60.59%↓ Y/Y)
Loss from operations
-$63,809K
(-65.72%↓ Y/Y)
Total revenues
$50,529K
(-3.92%↓ Y/Y)
Total operating
expenses
$114,338K
(25.52%↑ Y/Y)
Selling, general and
administrative
$71,838K
(11.18%↑ Y/Y)
Research and development
$36,953K
(68.04%↑ Y/Y)
Cost of goods sold
excluding amortization
$3,560K
(30.12%↑ Y/Y)
Intangible asset
amortization
$1,987K
(13.48%↑ Y/Y)
Buy us a coffee
Vanda Pharmaceuticals Inc. (VNDA)
Vanda Pharmaceuticals Inc. (VNDA)